JPH0825873B2 - 脳組織を保護するためのモダフィニル - Google Patents
脳組織を保護するためのモダフィニルInfo
- Publication number
- JPH0825873B2 JPH0825873B2 JP4332897A JP33289792A JPH0825873B2 JP H0825873 B2 JPH0825873 B2 JP H0825873B2 JP 4332897 A JP4332897 A JP 4332897A JP 33289792 A JP33289792 A JP 33289792A JP H0825873 B2 JPH0825873 B2 JP H0825873B2
- Authority
- JP
- Japan
- Prior art keywords
- modafinil
- treatment
- induced
- effect
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 229960001165 modafinil Drugs 0.000 title claims abstract description 38
- YFGHCGITMMYXAQ-UHFFFAOYSA-N 2-[(diphenylmethyl)sulfinyl]acetamide Chemical compound C=1C=CC=CC=1C(S(=O)CC(=O)N)C1=CC=CC=C1 YFGHCGITMMYXAQ-UHFFFAOYSA-N 0.000 title claims abstract description 37
- 210000005013 brain tissue Anatomy 0.000 title claims description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 claims abstract description 5
- 230000000694 effects Effects 0.000 claims description 18
- 208000028867 ischemia Diseases 0.000 claims description 7
- 206010008118 cerebral infarction Diseases 0.000 claims description 6
- 210000001723 extracellular space Anatomy 0.000 claims description 4
- 201000006474 Brain Ischemia Diseases 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 230000002253 anti-ischaemic effect Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 102100033902 Endothelin-1 Human genes 0.000 description 11
- 101800004490 Endothelin-1 Proteins 0.000 description 11
- 241000700159 Rattus Species 0.000 description 8
- 229960004046 apomorphine Drugs 0.000 description 8
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 8
- 210000001577 neostriatum Anatomy 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003447 ipsilateral effect Effects 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010061216 Infarction Diseases 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 210000000548 hind-foot Anatomy 0.000 description 3
- 230000007574 infarction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000508 neurotrophic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- 229940098778 Dopamine receptor agonist Drugs 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 229960003990 apomorphine hydrochloride Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 230000002025 microglial effect Effects 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- NPHOKTFQZAGWGP-UHFFFAOYSA-N n-benzhydrylsulfonylacetamide Chemical compound C=1C=CC=CC=1C(S(=O)(=O)NC(=O)C)C1=CC=CC=C1 NPHOKTFQZAGWGP-UHFFFAOYSA-N 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000004873 systolic arterial blood pressure Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/065—Diphenyl-substituted acyclic alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9115534 | 1991-12-13 | ||
| FR9115534A FR2684875B1 (fr) | 1991-12-13 | 1991-12-13 | Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH0665070A JPH0665070A (ja) | 1994-03-08 |
| JPH0825873B2 true JPH0825873B2 (ja) | 1996-03-13 |
Family
ID=9420051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4332897A Expired - Lifetime JPH0825873B2 (ja) | 1991-12-13 | 1992-12-14 | 脳組織を保護するためのモダフィニル |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US5391576A (Direct) |
| EP (1) | EP0547952B1 (Direct) |
| JP (1) | JPH0825873B2 (Direct) |
| KR (1) | KR100252390B1 (Direct) |
| AT (1) | ATE127342T1 (Direct) |
| AU (1) | AU656642B2 (Direct) |
| DE (1) | DE69204639T2 (Direct) |
| DK (1) | DK0547952T3 (Direct) |
| FR (1) | FR2684875B1 (Direct) |
| HU (2) | HU216193B (Direct) |
| TW (1) | TW244335B (Direct) |
| UA (1) | UA27231C2 (Direct) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697162B1 (fr) * | 1992-10-23 | 1995-01-13 | Lafon Labor | Utilisation du modafinil pour la fabrication d'un médicament pour le traitement de l'incontinence urinaire et des troubles sphinctériens urétro vésicaux. |
| FR2706767B1 (Direct) * | 1993-06-22 | 1995-09-08 | Lafon Labor | |
| FR2708201B1 (fr) * | 1993-06-30 | 1995-10-20 | Lafon Labor | Utilisation de dérivés d'acétamide pour la fabrication de médicaments. |
| US5618845A (en) | 1994-10-06 | 1997-04-08 | Cephalon, Inc. | Acetamide derivative having defined particle size |
| DE19943983A1 (de) * | 1999-09-14 | 2001-03-15 | Joseph Clasen | Verwendung von Modafinil zur Herstellung eines plastizitätsfördernden Arzneimittels |
| US20010034373A1 (en) * | 2000-02-09 | 2001-10-25 | Matthew Miller | Low dose modafinil for enhancement of cognitive function |
| US6492396B2 (en) * | 2000-05-16 | 2002-12-10 | Cephalon, Inc. | Substituted thioacetamides |
| HU229409B1 (en) * | 2000-10-11 | 2013-12-30 | Cephalon | Compositions comprising modafinil compounds |
| US7704975B2 (en) * | 2000-12-19 | 2010-04-27 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| US7141555B2 (en) * | 2000-12-19 | 2006-11-28 | Cephalon, Inc. | Modafinil compound and cyclodextrin mixtures |
| ES2281527T3 (es) * | 2001-05-25 | 2007-10-01 | Cephalon, Inc. | Formulaciones farmaceuticas solidas que comprenden modafinilo. |
| US20080058424A1 (en) * | 2002-05-23 | 2008-03-06 | Cephalon, Inc. | Novel pharmaceutical formulations of modafinil |
| US7229644B2 (en) * | 2002-05-23 | 2007-06-12 | Cephalon, Inc. | Pharmaceutical formulations of modafinil |
| US20040048931A1 (en) * | 2002-07-12 | 2004-03-11 | Craig Heacock | Modafinil pharmaceutical compositions |
| US6992219B2 (en) * | 2002-08-09 | 2006-01-31 | Cephalon France | Modafinil polymorphic forms |
| US20040116532A1 (en) | 2002-09-13 | 2004-06-17 | Craig Heacock | Pharmaceutical formulations of modafinil |
| IL153098A0 (en) * | 2002-11-26 | 2003-06-24 | Chemagis Ltd | Pharmaceutical compositions containing modafinil |
| EP1603867A2 (en) * | 2003-02-24 | 2005-12-14 | Mallinckrodt Inc. | Process for preparing benzhydrylthioacetamide |
| US20040253308A1 (en) * | 2003-04-29 | 2004-12-16 | Barr Laboratories, Inc. | Surface-treated modafinil particles |
| AR045423A1 (es) * | 2003-05-13 | 2005-10-26 | Cephalon Inc | Combinaciones de analiticos y antidepresivos |
| US7368591B2 (en) | 2003-09-19 | 2008-05-06 | Cephalon France | Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| US7449481B2 (en) | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US20060024370A1 (en) | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
| US20080181966A1 (en) * | 2006-10-18 | 2008-07-31 | Cephalon, Inc. | Modafinil pharmaceutical compositions |
| US20090325999A1 (en) * | 2008-06-27 | 2009-12-31 | Jie Du | Personalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions |
| EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
| KR101414831B1 (ko) * | 2011-10-25 | 2014-07-04 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 ＫＣａ3.1 채널 매개 질환 치료용 조성물 |
| KR101345860B1 (ko) * | 2011-10-25 | 2013-12-30 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 치료용 조성물 |
| WO2013062316A2 (ko) * | 2011-10-25 | 2013-05-02 | 이화여자대학교 산학협력단 | 모다피닐 또는 이의 유도체를 포함하는 혈관질환 또는 ＫＣａ3.1 채널 매개 질환 치료용 조성물 |
| CN105658227B (zh) | 2013-08-30 | 2020-04-03 | 绿十字生命健康有限公司 | 含有人参皂苷成分得到增加的加工人参粉末或加工人参提取物的用于预防及治疗癌因性疲乏的组合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1584462A (en) * | 1977-03-31 | 1981-02-11 | Lafon Labor | N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them |
| FR2593809B1 (fr) * | 1986-01-31 | 1988-07-22 | Lafon Labor | Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique |
| FR2663225B1 (fr) * | 1990-06-14 | 1994-11-04 | Lafon Labor | Nouvelle utilisation du modafinil. |
-
1991
- 1991-12-13 FR FR9115534A patent/FR2684875B1/fr not_active Expired - Lifetime
-
1992
- 1992-12-10 AU AU30080/92A patent/AU656642B2/en not_active Expired
- 1992-12-11 EP EP92403381A patent/EP0547952B1/fr not_active Expired - Lifetime
- 1992-12-11 HU HU9203921A patent/HU216193B/hu unknown
- 1992-12-11 AT AT92403381T patent/ATE127342T1/de active
- 1992-12-11 HU HU9203921A patent/HU9203921D0/hu unknown
- 1992-12-11 DE DE69204639T patent/DE69204639T2/de not_active Expired - Lifetime
- 1992-12-11 DK DK92403381.4T patent/DK0547952T3/da active
- 1992-12-12 KR KR1019920024095A patent/KR100252390B1/ko not_active Expired - Lifetime
- 1992-12-14 JP JP4332897A patent/JPH0825873B2/ja not_active Expired - Lifetime
- 1992-12-14 US US07/988,271 patent/US5391576A/en not_active Expired - Lifetime
-
1993
- 1993-01-27 TW TW082100506A patent/TW244335B/zh not_active IP Right Cessation
- 1993-06-18 UA UA93002196A patent/UA27231C2/uk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0547952B1 (fr) | 1995-09-06 |
| HUT67784A (en) | 1995-04-28 |
| HU216193B (hu) | 1999-05-28 |
| DK0547952T3 (da) | 1996-01-22 |
| HU9203921D0 (en) | 1993-03-29 |
| KR930012022A (ko) | 1993-07-20 |
| UA27231C2 (uk) | 2000-08-15 |
| AU3008092A (en) | 1993-06-17 |
| KR100252390B1 (ko) | 2000-05-01 |
| AU656642B2 (en) | 1995-02-09 |
| DE69204639T2 (de) | 1996-04-04 |
| ATE127342T1 (de) | 1995-09-15 |
| TW244335B (Direct) | 1995-04-01 |
| FR2684875B1 (fr) | 1995-05-24 |
| EP0547952A1 (fr) | 1993-06-23 |
| US5391576A (en) | 1995-02-21 |
| DE69204639D1 (de) | 1995-10-12 |
| FR2684875A1 (fr) | 1993-06-18 |
| JPH0665070A (ja) | 1994-03-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0825873B2 (ja) | 脳組織を保護するためのモダフィニル | |
| Behar et al. | Epidural morphine in treatment of pain | |
| Kastin et al. | Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease | |
| JP5201767B2 (ja) | 医薬組成物およびその調製方法 | |
| MX2008016017A (es) | Derivados de alfa-aminoamida utiles en el tratamiento de trastornos cognoscitivos. | |
| JPWO2019112007A1 (ja) | 鎮痛薬による眠気の予防または治療薬 | |
| WO2022261263A1 (en) | Methods of treating neuropsychiatric disorders | |
| JPH05504546A (ja) | 痛みのある疾患又はアレルギー性疾患の治療用組成物及び治療法 | |
| MX2013005014A (es) | Antagonistas a2a como mejoradores de la funcion cognitiva y motora. | |
| EP3096753A1 (en) | Use of indolyl and idolinyl hydroxamates for treating neurodegenerative disorders or cognitive deficits | |
| EP3057589B1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| He et al. | Clinical effect of sphenopalatine ganglion needling in treating primary trigeminal neuralgia of Liver-yang upsurge syndrome type | |
| BRPI0317795B1 (pt) | Derivados de alfa-aminoamida úteis como agentes antienxaqueca | |
| RS59687B1 (sr) | Oblici doziranja i terapeutske primene l-4-hlorkinurenina | |
| KR101146807B1 (ko) | 각성을 향상시키는 방법 | |
| CN113350357A (zh) | 羟基红花黄色素a和远志皂苷元的组合物在制备治疗缺血性脑卒中的药物中的应用 | |
| Lin et al. | The mechanistic studies of acupuncture and moxibustion in Taiwan | |
| Caraceni et al. | Bromocriptine alone or associated with L-dopa plus benserazide in Parkinson's disease. | |
| WO2023226381A1 (zh) | 一种吲哚化合物及制备方法与应用 | |
| CN111773204B (zh) | 二氯乙酸钠在制备治疗血管性痴呆药物中的用途 | |
| US8182844B2 (en) | Use of Clerodendrum sp. for treating tic disorders or psychiatric disorders with sensorimotor gating deficits | |
| CN113209064A (zh) | 白花丹醌在制备预防或治疗帕金森病药物中的应用 | |
| Khan et al. | Effect of perineural administration of Dexmedetomidine with Bupivacaine versus Bupivacaine alone in ultrasound guided supraclavicular block for upper extremity orthopaedic operations | |
| JPH09500375A (ja) | パーキンソン病の治療を目的とする医薬品の製造のためのエファロキサンおよびその誘導体の使用 | |
| Sukariada et al. | The Effectivity of Ethanol Extract of Datura Metel L. Seeds as a General Anaesthesia on Kintamani Dogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080313 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090313 Year of fee payment: 13 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100313 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100313 Year of fee payment: 14 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110313 Year of fee payment: 15 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 16 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120313 Year of fee payment: 16 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 17 |
|
| EXPY | Cancellation because of completion of term | ||
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130313 Year of fee payment: 17 |